DOD Archives • Fragile X Research - FRAXA Research Foundation

Department of Defense Medical Research Funding Guided by FRAXA Consumer Reviewers

FRAXA Research Foundation Advocacy November 17, 2020DOD, PRMRP

FRAXA nominated three individuals to join in the program this year. Over the past several weeks, Katie Clapp, Ellen Skala, and Jennifer Frobish participated in the evaluation of research applications submitted to the PRMRP. As consumer reviewers, they were full voting members (along with prominent scientists) at meetings to help determine how the $360 million appropriated by Congress for Fiscal Year 2020 will be spent on PRMRP research.

Mechanisms and Biomarkers of Sensory Hypersensitivity in the fmr1 Knockout Mouse

FRAXA Research Foundation Binder, Devin • Razak, Khaleel • Research Updates • Seminar Series August 27, 2020August 27, 2020astrocytes, DOD, EEG, glutamate, Healx, hypersensitivity, matrix metalloproteinase, NIH, seizure, sound

In this Fragile X research webinar we hear from Devin K. Binder, MD, PhD, Professor, University of California at Riverside Medical School and Khaleel Razak, PhD, Professor, University of California at Riverside as they present about Mechanisms and Biomarkers of Sensory Hypersensitivity in the fmr1 Knockout Mouse.

Mechanisms and Biomarkers of Sensory Hypersensitivity in the fmr1 Knockout Mouse

FRAXA Research Foundation August 4, 2020August 27, 2020astrocytes, DOD, EEG, glutamate, hypersensitivity, matrix metalloproteinase, NIH, seizure, sound

This is the second in a series of webinars focused on current topics in Fragile X research. Devin K. Binder, MD, PhD, Professor, University of California at Riverside Medical School and Khaleel Razak, PhD, Professor, University of California at Riverside will present.

Federal Funding for Fragile X Research Faces Snags

Katie Clapp Advocacy • FRAXA Updates February 21, 2019June 5, 2019DOD, NIH

We in the Fragile X community have our advocacy work cut out for us to restore levels of federal funding for Fragile X research! Both of the main federal funders – the National Institutes of Health (NIH) and the Department of Defense (DOD) are letting Fragile X research lapse!

President Clinton celebrating Children's Health Act

Department of Defense (DOD) Discontinues Fragile X Research Funding

FRAXA Research Foundation Advocacy December 13, 2018February 21, 2019DOD, PRMRP

FRAXA’s Katie Clapp learned that Fragile X, which has been an approved topic since 2010, is not on the list of approved topics for 2019 for DOD’s Peer Reviewed Medical Research Program (PRMRP). In order for Fragile X Research to be on the approved topics for the DOD’s PRMRP funding for next year we need your help.

Western Homesteading Adventure-Fragile X Style

FRAXA Research Foundation Fundraising Campaigns December 3, 2018February 25, 2019CRISPR, DOD, FDA

Two years ago, we marshalled our courage and our possessions and set out on our personal Western Homesteading Adventure — Fragile X style. Unlike the Westward Expansion of the mid 1800’s we were not offered a plot of land to settle, but it sure felt like we were taking a huge leap of faith by packing up our life in Detroit and heading West.

Contacting Your Member of Congress in Support of Fragile X Advocacy

FRAXA Research Foundation Advocacy December 1, 2018June 26, 2019autism, DOD, NIH

Important information about how best to contact your Member of Congress in support of Fragile X advocacy, including tips, recommendations, best practices and how to get contact info for your state senators and representatives.

Fragile X Fruit Fly Research Bears Fruit

FRAXA Research Foundation Jongens, Tom • McBride, Sean • Research Updates April 26, 2016December 26, 2019autism, DOD, fruit fly, metformin, NIH, sleep

A new FRAXA-funded study shows how the hormone insulin – usually associated with diabetes — is involved in the daily activity patterns and learning deficits in the fruit fly model of Fragile X Syndrome (FXS). The study also reveal a metabolic pathway that can be targeted by new and already approved drugs to treat Fragile X patients, notably metformin.